March, 2024
March 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Vivek Subbiah: Pleased to share our editorial in  on Direct-to-Patient Clinical Trials
Feb 13, 2024, 01:50

Vivek Subbiah: Pleased to share our editorial in on Direct-to-Patient Clinical Trials

Vivek Subbiah shared a post on LinkedIn:

“Pleased to share our editorial in American Association for Cancer Research journal Clinical Cancer Research on Direct-to-Patient Clinical Trials.

Genome driven precision oncology has transformed the landscape of multiple cancers. However, access barriers exist. A recent study exemplified a direct-to-patient outreach program via social media through the implementation of a global program that offered free tumor genomic testing with a focus on rare cancers.”

View additional information.
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.